Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose nearly 7% in early trading, Argenx FcRn Targeted Drug Phase 3 successfully Zaiding has interests in Greater China

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose nearly 7% in early trading. As of press release, it had risen 4.61% to HK$20.18, with a turnover of HK$131 million.

According to the news, according to the Pharmaceutical Research Network, on August 17, the immunology company Argenx announced that the ALKIVIA phase 3 clinical study on the core product FcRN antagonist (agamod alpha) flag to treat autoimmune myositis in adults has achieved positive top-line results. Notably, Argenx previously granted Agamod's exclusive development and commercialization rights in Greater China to Zaiding Pharmaceuticals.

It is worth noting that the AlkiVIA study itself is a phase 3 global study initiated by ArgenX, and Zaiding Pharmaceutical also participated in clinical development and patient enrollment in Greater China. If this indication is later approved globally, Zaiding is expected to further expand the commercialization of Agamod in the field of autoimmune diseases in China.